<DOC>
	<DOCNO>NCT02882659</DOCNO>
	<brief_summary>The primary objective study evaluate safety autologous dendritic killer cell ( DKC ) patient metastatic solid tumor evaluate maximum tolerate dose ( MTD ) DKC . The primary endpoint safety evaluation include physical examination , assessment vital sign , laboratory test , concomitant medication , adverse event ( AE ) . The secondary endpoint regard efficacy include generation tumor specific immune response detect CD3+ CD8+ CD69+ IFN-gamma+ T cell , improvement quality life</brief_summary>
	<brief_title>Dendritic Killer Cell-based Immunotherapy Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>1 . Capable willing providing sign informed consent study 2 . Patient age ≥20 date consent 3 . Performance status ( ECOG ) ≤2 4 . Patients life expectancy &gt; 3 month 5 . Patients agree compliant clinical protocol plan treatment plan 6 . Histologically confirm metastatic solid tumor , include colon cancer , gastric cancer , pancreatic cancer , bile duct cancer , liver cancer 7 . Patient histological conventional image proven measurable lesion 8 . Patients pregnant . All male female patient reproduction ability use appropriate contraception method ( ) study period 9 . Patient currently immunosuppressive treatment previous recur autoimmune disease 10 . Patient receive fail prior standard cancer therapy ( accord TVGH standard cancer treatment procedure , National Comprehensive Cancer Network clinical practice guideline oncology ) 11 . Patient adequate hematology function : Absolute neutrophil count ( ANC ) ≥ 1,500 cell Total white blood cell ( WBC ) ≥ 3,000 cell /mm3 Hemoglobin ≥ 9 g/dl Platelets ≥ 100,000 count /mm3 12 . Patient adequate hepatic renal function Serum creatinine ≤ 1.5X Upper Limit Normal ( ULN ) Total bilirubin ( TB ) ≤ 1.5X ULN , ≤ 2.5X ULN patient primary HCC liver metastasis ALT AST ≤ 2.5X ULN , ≤ 5X ULN patient primary HCC liver metastasis Alkaline phosphatase ( ALP ) ≤ 5X ULN 13 . Patient show negative response syphilis , HIV , HBV HCV test 1 . Any investigational drug use within 28 day prior first DKC administration 2 . Patient known brain metastasis metastasis central nervous system 3 . Patient pulmonary fibrosis 4 . Patient pleural effusion cite correspond CTCAE grade &gt; 2 5 . Patient uncontrolled disease include limit cardiovascular disease , liver disease , renal disease infectious disease 6 . Patients diagnose cognitive psychiatric illness 7 . Patient suitable participate trial safety concern judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Clinical Trial , Phase I</keyword>
</DOC>